Kenvue Inc. KVUE SPXR3K
Company Overview
Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as other naturally inspired and self-care products, digital diagnostics, and telemedicine; face and body care, hair, sun, and other care products; oral and baby care, women's health, wound care, and other essential health products; tampons; cosmetics; and vitamins and supplements. It sells its products under the Benadryl, Calpol, Motrin, Nicorette, Rhinocort, Tylenol, Zarbee's Naturals, and Zyrtec; Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Neutrogena, OGX, and Rogaine; BAND-AID, Carefree, Desitin, Johnson's, Listerine, o.b., and Stayfree; and ORSL, Clean & Clear, Versalie, Benylin, Daktarin, Imodium, Johnson's Baby, Johnson's Adult, Maui Moisture, Microlax, Motilium, Neosporin, Neostrata, Pepcid, Pulmicort, Regaine, Sudafed, and Visine/Vispring/Visclear brands. Kenvue Inc. was incorporated in 2022 and is headquartered in Summit, New Jersey.
Why Investors Should Care
Generates a return on equity of 15.6%, reflecting efficient use of shareholder capital.
Operating margin of 19.4% supports profitability.
Offers a dividend yield of 4.70%.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $15.12B (-2.1% YoY); net profit $1.47B.
- Trailing 12 Months Year-on-year growth — revenue +3.0%, earnings +8.5%.
- 5-Year Trend Long-term compounding — revenue CAGR 0.1%, profit CAGR -8.3%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 0.12% |
| 1 Year: | 3.00% |
Compounded Profit Growth
| 5 Years: | -8.29% |
| 1 Year: | 8.50% |
Stock Price Performance
| 1 Year: | -4.02% |
| 6 Months: | +17.70% |
| 3 Months: | +5.51% |
| 1 Month: | +12.51% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)74.73 · Overbought
P/E of 23.39 is above the sector median of 19.94 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Attractive dividend yield of 4.70%.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Earnings shrank at -8.3% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Consumer Defensive).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | KVUE Kenvue Inc. SPXR3K | 19.88 | 23.39 | $38.18B | 4.70% | 11.42% | 15.58% | 0.12% | -8.29% |
| 2 | WMT Walmart Inc. SPXR3K | 121.12 | 43.88 | $960.94B | 0.93% | 16.83% | 22.31% | 3.82% | 3.24% |
| 3 | COST Costco Wholesale Corporation NDXSPXR3K | 1,018.21 | 49.09 | $451.20B | 0.62% | 25.96% | 28.40% | 8.16% | 11.45% |
| 4 | KO The Coca-Cola Company SPXR3K | 95.34 | 28.63 | $410.21B | 2.41% | 16.47% | 42.05% | 2.86% | 4.46% |
| 5 | PG The Procter & Gamble Company SPXR3K | 165.59 | 25.01 | $384.90B | 2.95% | 22.49% | 30.29% | 0.52% | 1.59% |
| 6 | PM Philip Morris International Inc. SPXR3K | 201.74 | 27.71 | $314.43B | 3.09% | 34.03% | -113.55% | -1.69% | 3.57% |
| 7 | PEP PepsiCo, Inc. NDXSPXR3K | 138.83 | 18.20 | $189.64B | 4.43% | 15.41% | 51.51% | 4.93% | 2.11% |
| 8 | BUD Anheuser-Busch InBev SA/NV | 85.49 | 18.42 | $149.36B | 1.80% | 8.49% | 11.39% | 0.88% | 4.63% |
| 9 | MO Altria Group, Inc. SPXR3K | 76.07 | 16.01 | $127.02B | 6.37% | 38.27% | - | 1.24% | -1.89% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Apr 2022 | Jul 2022 | Oct 2022 | Jan 2023 | Apr 2023 | Jul 2023 | Oct 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.59B | 3.80B | 3.79B | 3.77B | 3.85B | 4.01B | 3.92B | 3.67B | 3.89B | 4.00B | 3.90B | 3.74B | 3.84B | 3.76B | 3.91B | 3.96B |
| Gross Profit | 1.96B | 2.16B | 2.12B | 2.05B | 2.12B | 2.23B | 2.25B | 2.04B | 2.24B | 2.37B | 2.28B | 2.17B | 2.26B | 2.23B | 2.30B | 2.30B |
| Operating Income | 611.00M | 770.00M | 763.00M | - | 640.00M | 702.00M | 710.00M | - | 550.00M | 154.00M | 654.00M | 558.00M | 692.00M | 629.00M | 767.00M | 699.00M |
| Net Income | 512.00M | 605.00M | 586.00M | 361.00M | 469.00M | 430.00M | 438.00M | 327.00M | 296.00M | 58.00M | 383.00M | 322.00M | 420.00M | 398.00M | 474.00M | 456.00M |
| Diluted EPS | 0.30 | 0.35 | 0.34 | 0.21 | 0.27 | 0.23 | 0.23 | 0.17 | 0.15 | 0.03 | 0.20 | 0.17 | 0.22 | 0.21 | 0.25 | 0.24 |
| R&D Expense | 88.00M | 94.00M | 90.00M | - | 89.00M | 99.00M | 78.00M | - | 100.00M | 105.00M | 97.00M | 99.00M | 91.00M | 94.00M | 84.00M | 94.00M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Jan 2022 | Jan 2023 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 15.05B | 14.95B | 15.44B | 15.46B | 15.12B |
| Gross Profit | 8.42B | 8.29B | 8.64B | 8.96B | 8.79B |
| Operating Income | 2.92B | 2.67B | 2.51B | 1.84B | 2.41B |
| Net Income | 2.08B | 2.06B | 1.66B | 1.03B | 1.47B |
| Diluted EPS | 1.21 | 1.20 | 0.90 | 0.54 | 0.76 |
| R&D Expense | 355.00M | 375.00M | 399.00M | 408.00M | 382.00M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jan 2021 | Dec 2021 | Jan 2022 | Dec 2022 | Jan 2023 | May 2023 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | - | 27.32B | 27.32B | - | 27.85B | 25.60B | 27.08B |
| Current Assets | - | - | - | 5.88B | - | - | 6.14B | 5.53B | 5.70B |
| Cash & Equivalents | - | - | - | 1.23B | 1.23B | 1.17B | 1.38B | 1.07B | 1.06B |
| Inventory | - | - | - | 2.23B | - | - | 1.85B | 1.59B | 1.67B |
| Receivables | - | - | - | 2.12B | - | - | 2.07B | 2.17B | 2.38B |
| Total Liabilities | - | - | - | 7.35B | 7.35B | - | 16.64B | 15.93B | 16.31B |
| Current Liabilities | - | - | - | 3.93B | 3.93B | - | 5.48B | 5.74B | 5.95B |
| Long Term Debt | - | - | - | 8.93B | 0 | - | 7.69B | 6.94B | 6.94B |
| Total Debt | - | - | - | 116.00M | - | - | 8.43B | 8.72B | 8.67B |
| Total Equity | 18.40B | - | 20.49B | 19.97B | 19.97B | - | 11.21B | 9.67B | 10.77B |
| Shares Outstanding | - | - | - | 1.89B | - | - | 1.92B | 1.92B | 1.94B |
Cash Flows (Annual)
Figures in USD.
| Metric | Jan 2022 | Jan 2023 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | 334.00M | 2.52B | 3.17B | 1.77B | 2.20B |
| Investing Cash Flow | -171.00M | -390.00M | -488.00M | -425.00M | -436.00M |
| Financing Cash Flow | 0 | -1.58B | -2.53B | -1.56B | -1.84B |
| Capital Expenditure | -295.00M | -375.00M | -469.00M | -434.00M | -475.00M |
| Free Cash Flow | 39.00M | 2.15B | 2.70B | 1.33B | 1.72B |
| Share Buybacks | - | 0 | 7.00M | 235.00M | 197.00M |
| Dividends Paid | 0 | 0 | 766.00M | 1.55B | 1.58B |
Ratios (Annual)
Figures in %.
| Metric | Jan 2022 | Jan 2023 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | 55.9% | 55.4% | 56.0% | 58.0% | 58.1% |
| Operating Margin % | 19.4% | 17.9% | 16.3% | 11.9% | 16.0% |
| Net Margin % | 13.8% | 13.8% | 10.8% | 6.7% | 9.7% |
| ROE % | 10.1% | 10.3% | 14.8% | 10.7% | 13.7% |
| ROCE % | - | 11.4% | 11.2% | 9.3% | 11.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 8.18% | 157.05M | $2.78B |
| 2 | Blackrock Inc. | 7.85% | 150.83M | $2.67B |
| 3 | Vanguard Capital Management LLC | 6.52% | 125.31M | $2.22B |
| 4 | State Street Corporation | 6.33% | 121.62M | $2.15B |
| 5 | Vanguard Portfolio Management LLC | 4.86% | 93.30M | $1.65B |
| 6 | Geode Capital Management, LLC | 2.71% | 52.02M | $920.78M |
| 7 | Pentwater Capital Management Lp | 2.66% | 51.13M | $905.00M |
| 8 | Independent Franchise Partners, LLP | 2.63% | 50.43M | $892.58M |
| 9 | NORGES BANK | 2.40% | 46.16M | $816.98M |
| 10 | Massachusetts Financial Services Co. | 2.33% | 44.72M | $791.47M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for KVUE
Indonesian leader rejects market downgrade warning after stock market sell-off - KVUE
<a href="https://news.google.com/rss/articles/CBMihwJBVV95cUxQWTNrUGR3d3BSR1FxLWdCU3NIZFFnZldMY1RjNlpsUVB4dmF2UDBicU0yb0lxMmhkczFCTEkxV1hvaVFnb043YTlDbmhWdXB4YjBoQUF2VE1wRERZeEs1WDhFTUIwVVFvOENjY2dkbkhRR1M0NHNIazd3aDlMT0NTdUZEZWVac0NONmpoek…
How to Buy Kenvue Stock (KVUE) in 2026 - The Motley Fool
<a href="https://news.google.com/rss/articles/CBMiigFBVV95cUxNMy1QY1E4ZHZlbzJreWtDeExsakszZ0JGM2l5YjN1YkxoclZETlBPM2dxTzVXbTVUQklBdC1vZlNGY3RaOWpRNXphLTFOZHpHRndTRzRnRDFTMzc3dWtOVFF2cTN5bHZfUHZtVlplMEF5bURFTUpPRFhqbnFlQm9HdXU4RHJGYkNDdlE?oc…
KVUE Nov 2026 15.500 put (KVUE261113P00015500) Stock Historical Prices & Data - Yahoo! Finance Canada
<a href="https://news.google.com/rss/articles/CBMicEFVX3lxTFBuR2pPMnNaYnV5NXgtNXhxdnl1Q09KLVFhd0RERVQ4ck9ObGxhZ0h3VWpLZVpOWW9RSnN3cVZRRVFkYXo2TExqMkl2OVhISGNPVzY2SkJ3VkFUYVNQc3lsLW9TWXlJeEtsZ0RCZXRCY2g?oc=5" target="_blank">KVUE Nov 2026 15…
Kenvue Inc. Stock Grades | KVUE - Barron's
<a href="https://news.google.com/rss/articles/CBMinAJBVV95cUxNSGppVzdVXzduOXdOd0FHd2F3bzcxSlhXSkw1SWktaXJob0hoWkg2VUNpNGhScTRxNV9LeFpaWVV6ZDBwNElrYXVmcEdIdTNtV3BLOEhRVFZoOWRkRmJHVEtKTzVuQ2ZpcElqZVUtQnA1TU10aVhGdEhfWS02TGlSN1RLbE9lMWp1bHhEYW…
KVUE Stock Technical Analysis - Pluang
<a href="https://news.google.com/rss/articles/CBMiaEFVX3lxTFBlZmpQSkhvbmllRVpIRWVnajhoV2kxbUZlMDVQcFU3Q2l6elJuU0IxLTNYcml0cTNqMzBXc2VzODdxVGV5c2NiUnZCWUVaaHFLbFd2RlpGbDNkN19XQ2RiYUl4bnRla0M1?oc=5" target="_blank">KVUE Stock Technical Analys…
How major US stock indexes fared Tuesday 10/20/2026 - KVUE
<a href="https://news.google.com/rss/articles/CBMi4AFBVV95cUxNQVR4cVRnc01QSWR6MURCSGtsZ21JdWhpTjI2d3pZMkRWR2w0QU9WdXNZQmRUOVNVWk5SVjl1M3l1TTJjVV8zcXNiUnY0VUdlcnA3bUtldmNZZXJYbzJVSFhqS05vYU5maGhjM1BXdm1kckQ0a0tMVmFJUnUxLU1BSU1qNjFPMkVkMnR4eV…
KVUE — Frequently Asked Questions
What is the current share price of Kenvue Inc. (KVUE)?
As of 2026-10-22 16:30 PDT, Kenvue Inc. (KVUE) trades at $19.88 on NYSE. Its 52-week range is $13.30 to $20.71.
What is the market capitalisation of KVUE?
Kenvue Inc. (KVUE) has a market capitalisation of $38.18B on NYSE.
What is the P/E ratio of KVUE?
KVUE trades at a trailing price-to-earnings (P/E) ratio of 23.39. The industry average P/E is 19.94. Its price-to-book (P/B) ratio is 3.24.
Does KVUE pay a dividend?
Kenvue Inc. (KVUE) currently offers a dividend yield of 4.70%.
What is the return on equity (ROE) of KVUE?
KVUE has a return on equity (ROE) of 15.58%. Its return on capital employed (ROCE) is 11.42%.
Is KVUE a good stock to buy?
This page provides a data-driven analysis of Kenvue Inc. (KVUE), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.